Eyepoint Pharmaceuticals

Yahoo Finance • 29 days ago

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

Key Points Cormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 shares in the fourth quarter. The value of the position was $68.75 million at quarter-end. The new position places Olema outside... Full story

Yahoo Finance • 30 days ago

This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment

On February 17, 2026, Parkman Healthcare Partners disclosed a new position in EyePoint(NASDAQ:EYPT), acquiring 1,088,033 shares in the fourth quarter. What happened According to a Securities and Exchange Commission (SEC) filing dated Feb... Full story

Yahoo Finance • last month

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Ocugen (OCGN [https://seekingalpha.com/symbol/OCGN]) * Abercrombie & Fitch Co. (ANF [https://seekingalpha.com/symbol/ANF]) * XAI Octagon Floating Rate & Alternative Inc... Full story

Yahoo Finance • last month

Pre-Market Earnings Report for March 4, 2026 : DY, NXE, BBWI, ANF, WIX, EYE, EYPT, GENI, DAKT, STVN, OCGN, REAX

The following companies are expected to report earnings prior to market open on 03/04/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Dycom Industries, Inc. (DY)is reporting for the quarter ending Janua... Full story

Yahoo Finance • 4 months ago

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents 0.31% of Cormorant’s reportable 13F as... Full story

Yahoo Finance • 5 months ago

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – – On track to report topline 56-week data for LU... Full story

Yahoo Finance • 5 months ago

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME program consisting of two identical non-inferiority tria... Full story

Yahoo Finance • 6 months ago

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseas... Full story

Yahoo Finance • 6 months ago

Biggest stock movers Wednesday: VERI, PZZA, and more

[Emerging Financial Data - Stock Market, Prosperity, Bull Market - Blue Version] DKosig Stock futures edged up early Wednesday, as investors braced for a busy day of corporate earnings reports and watched for signals on the Federal Reserv... Full story

Yahoo Finance • 6 months ago

EyePoint prices public offering at $12.00 per share, raises $150M to boost DURAVYU™ Phase 3 clinical programs

EyePoint Pharmaceuticals (NASDAQ:EYPT [https://seekingalpha.com/symbol/EYPT]) has announced the pricing [https://seekingalpha.com/pr/20266005-eyepoint-announces-pricing-of-public-offering] of an underwritten public offering expected to gen... Full story

Yahoo Finance • 6 months ago

EyePoint Announces Pricing of Public Offering

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseas... Full story

Yahoo Finance • 6 months ago

EyePoint Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseas... Full story

Yahoo Finance • 6 months ago

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New preclinical data demonstrates that vorolani... Full story

Yahoo Finance • 7 months ago

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, t... Full story

Yahoo Finance • 8 months ago

EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseas... Full story

Yahoo Finance • 8 months ago

National Vision stock price target raised to $33 at Jefferies

Investing.com - Jefferies raised its price target on National Vision Holdings (NASDAQ:EYE) to $33.00 from $22.00 on Monday, while maintaining a Buy rating on the stock. The company, currently trading at $22.64 with a market capitalizatio... Full story

Yahoo Finance • 8 months ago

EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Q2 2025 Earnings Miss Estimates as Shares Drop 4.5% Pre-Market

EYEPOINT PHARMACEUTICALS INC (NASDAQ:EYPT [https://www.chartmill.com/stock/quote/EYPT/profile]) REPORTS Q2 2025 EARNINGS: MISSES ESTIMATES AS MARKET REACTS NEGATIVELY EyePoint Pharmaceuticals Inc. released its second-quarter 2025 financia... Full story

Yahoo Finance • 8 months ago

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseas... Full story

Yahoo Finance • 8 months ago

EyePoint Pharmaceuticals GAAP EPS of -$0.85 misses by $0.04, revenue of $5.3M misses by $0.86M

* EyePoint Pharmaceuticals press release [https://seekingalpha.com/pr/20190701-eyepoint-reports-second-quarter-2025-financial-results-and-highlights-recent-corporate] (NASDAQ:EYPT [https://seekingalpha.com/symbol/EYPT]): Q2 GAAP EPS of -... Full story

Yahoo Finance • 8 months ago

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-wee... Full story